Navigation Links
Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Date:4/17/2017

SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled for Thursday, April 27, 2017, at 9:55 am ET.

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:
Investor Contact:
Thomas Soloway, CFO
415.818.1040
ir@audentestx.com

Media Contact:
Jeffrey Gruis
415.818.1015
media@audentestx.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-the-arm-5th-annual-cell--gene-therapy-investor-day-300440070.html


'/>"/>
SOURCE Audentes Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
2. Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
3. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
4. United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
8. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
9. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
10. FACIT Announces Investment in Propellon Therapeutics
11. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the BIO World Congress ... Association (NCGA) announced the winners of the Consider Corn Challenge II. Three winners ... field corn to produce biobased materials. , “Corn is a sustainable, abundant and ...
(Date:7/2/2019)... ... 2019 , ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , was ... The film focuses on regenerative veterinary medicine as a means of improving the quality ... in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, California ...
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC ... into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector ... autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries, ... been signed. The agreement will grant exclusive rights for Zillion to represent LDA ...
Breaking Biology Technology:
(Date:6/11/2019)... ... June 10, 2019 , ... Improved Pharma LLC announces the ... issue of AAPS PharmSciTech. The article was published online on April 29th, 2019. The ... along with Xiaoming Sean Chen of Purdue University. , The article is the most ...
(Date:6/6/2019)... CHICAGO (PRWEB) , ... June 05, 2019 , ... ... its role as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on ... is a preeminent anatomic pathology platform that provides services to more than one ...
(Date:6/4/2019)... ... June 04, 2019 , ... Harper was three years old when her owners ... dysplasia, which caused painful osteoarthritis in the joints. She was referred to a ... , The surgical specialist, Dr. Christopher Eich of Southern California Veterinary Specialty Hospital ...
Breaking Biology News(10 mins):